SYDNEY: CardieX Limited has engaged leading mobile App, and software infrastructure developer MEDL Mobile to undertake the development and design of a consumer facing App that will interface with the world’s first consumer non-invasive Central Blood Pressure Monitor (cBPM).

MEDL will also develop a clinician portal that will connect clinicians and health professionals with CardieX’s devices and wearables; and development and design of features and applications to be incorporated into the Mobvoi smart-watch pursuant to the CardieX/Mobvoi Joint Development Agreement, as well as all future wearable partnerships.

Software and App strategy expands CardieX’s revenue model from device sales and leasing to also include subscription and digital revenue from App sales, SaaS revenue, and subscriptions from consumers and clinicians.

Investors have previously been briefed as to CardieX’s new product and wearable strategy which incorporates new wearable technology in development with Mobvoi and Blumio, as well as new devices in development by CardieX that are due for launch in Q3, 2021.

Supporting all device and product development is the development of a suite of Apps, software, and cloud infrastructure that will provide multiple new revenue streams for the Company. The clinician portal will be a clinical facing web App that will allow physicians to view patient data collected from CardieX’s cBPM devices and will help physicians bill for the remote blood pressure CPT codes as well as the central blood pressure CPT code, which allows clinicians to be reimbursed for using CardieX technology.

The consumer App will be a subscription-based App built on CardieX’s technology that will provide consumers, athletes, and those with inflammation, heart, brain, and other vascular disorders with preventative information for managing their health, wellness, and fitness.

Edited by Kazim Rizvi